Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Clinical trial data from the SURMOUNT-1 study showed that gastrointestinal adverse events were significantly more common during dose escalation periods (Jastreboff et al., 2022, NEJM)
RNA from PYY-treated and untreated organoids underwent qPCR to assess PPAR- target gene expression, including ADRP, CD36, FABP, and LPL
The main findings so far are dose-dependent weight loss in phase 2 studies, frequent gastrointestinal side effects, and ongoing questions about long-term safety, eligibility, and approval
Chou CY, Chang YT, Yang JL, Wang JY, Lee TE, Wang RY, Hung CC
US$ 20.23
US$ 20.80
US$ 23.05
US$ 24.93
US$ 27.19
US$ 21.05
US$ 26.06
US$ 23.73
